Hanseo to invest 1 billion won for bio R&D infra.

Published: 2005-11-01 06:56:00

Updated: 2005-11-01 06:56:00

Hanseo announced on Oct. 27 that the total one billion won of investment would be made to Bio Infra and Nuvex, where Prof. Kim Cheol-woo of SNU hospital is the CEO and a majority shareholder, and these two companies already planned to merge in Dec. this year.

According to the agreement, Hanseo...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK